EP Patent

EP4529927A2 — Compositions and methods for modulating hbv and ttr expression

Assigned to Ionis Pharmaceuticals Inc · Expires 2025-04-02 · 1y expired

What this patent protects

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

USPTO Abstract

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

Drugs covered by this patent

Patent Metadata

Patent number
EP4529927A2
Jurisdiction
EP
Classification
—
Expires
2025-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Ionis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.